Review



cd3ε antibody, anti-mouse, reafinity  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Miltenyi Biotec cd3ε antibody, anti-mouse, reafinity
    Cd3ε Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 47 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/custom%40130-133-367%4042526445
    Average 99 stars, based on 47 article reviews
    cd3ε antibody, anti-mouse, reafinity - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    other:

    Article Title: Tac1 deficiency reduces the severity of enteric bacterial infection.
    Article Snippet: bo Biosciences 30-5941-U100 CD45 30-FF1 efluor450 eBioscience 48-0451-82 CD3 145-2C11 APC Tonbo Biosciences 20-0031-U100 CD4 V4 AF700 Biolegend 100430 CD4 RM4–5 FITC BD Pharmogen 553047 CD64 REA286 PE Miltenyi Biotec 130-118-684 Ly6G 1A8 FITC Tonbo Biosciences 35-1276-U100 Ly6C HK1.4 PE-Cy7 Invitrogen 25-5932-82 gp38 8.1.1 AF488 Biolegend 127405 CD31 MEC13.3 APC/Cyanine7 Biolegend 102533 IL17a XMG1



    Similar Products

    99
    Miltenyi Biotec cd3ε antibody, anti-mouse, reafinity
    Cd3ε Antibody, Anti Mouse, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/custom%40130-133-367%4042526445
    Average 99 stars, based on 1 article reviews
    cd3ε antibody, anti-mouse, reafinity - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    94
    Multi Sciences (Lianke) Biotech Co Ltd anti mouse cd3ε monoclonal antibodies
    Anti Mouse Cd3ε Monoclonal Antibodies, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/Anti-Mouse+CD3%CE%B5/pmc13405235-55-8-15
    Average 94 stars, based on 1 article reviews
    anti mouse cd3ε monoclonal antibodies - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    97
    Bio X Cell anti cd3 antibody
    Anti Cd3 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/InVivoMAb+anti-mouse+CD3%CE%B5/pm42864360-491-39-41
    Average 97 stars, based on 1 article reviews
    anti cd3 antibody - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd3ε antibody, anti-mouse
    Cd3ε Antibody, Anti Mouse, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse/custom%40130-121-440%4010%2E1158%2F2159-8290%2Ecd-25-1411
    Average 94 stars, based on 1 article reviews
    cd3ε antibody, anti-mouse - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd3 antibody
    Cd3 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/pmc13129426-7-0-9
    Average 99 stars, based on 1 article reviews
    cd3 antibody - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd3 microbeads
    Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, <t>CD3</t> + T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com . (B and C) Flow cytometric analysis of CD19-CAR + frequency (B) and CD19-CAR molecules per cell (C) in CD3 + , CD4 + , and CD8 + T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com . (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR + frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3 + T cells, 8 h after mRNA transfection ( n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com . (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR + GFP + double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection ( n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.
    Cd3 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/pmc13139981-219-23-25
    Average 99 stars, based on 1 article reviews
    cd3 microbeads - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec anti cd3
    Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, <t>CD3</t> + T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com . (B and C) Flow cytometric analysis of CD19-CAR + frequency (B) and CD19-CAR molecules per cell (C) in CD3 + , CD4 + , and CD8 + T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com . (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR + frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3 + T cells, 8 h after mRNA transfection ( n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com . (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR + GFP + double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection ( n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.
    Anti Cd3, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/us12630802-622-27-29
    Average 99 stars, based on 1 article reviews
    anti cd3 - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec anti human cd3 microbeads
    Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, <t>CD3</t> + T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com . (B and C) Flow cytometric analysis of CD19-CAR + frequency (B) and CD19-CAR molecules per cell (C) in CD3 + , CD4 + , and CD8 + T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com . (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR + frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3 + T cells, 8 h after mRNA transfection ( n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com . (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR + GFP + double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection ( n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.
    Anti Human Cd3 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3%CE%B5+antibody%2C+anti-mouse/CD3%CE%B5+Antibody%2C+anti-mouse%2C+REAfinity/pm42144489-51-15-18
    Average 99 stars, based on 1 article reviews
    anti human cd3 microbeads - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    Image Search Results


    Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, CD3 + T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com . (B and C) Flow cytometric analysis of CD19-CAR + frequency (B) and CD19-CAR molecules per cell (C) in CD3 + , CD4 + , and CD8 + T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com . (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR + frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3 + T cells, 8 h after mRNA transfection ( n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com . (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR + GFP + double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection ( n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation

    doi: 10.1016/j.omtn.2026.102929

    Figure Lengend Snippet: Transfection efficacy of CD19-CAR mRNA and co-expression of multiple IVT mRNAs in polyclonally activated T cells (A) Experimental workflow: PBMCs from healthy donors were isolated, CD3 + T cells enriched by MACS, polyclonally activated with plate-bound anti-CD3/CD28 antibodies for 48 h, and electroporated with IVT mRNA on day 3. Created with BioRender.com . (B and C) Flow cytometric analysis of CD19-CAR + frequency (B) and CD19-CAR molecules per cell (C) in CD3 + , CD4 + , and CD8 + T cell subsets at 8 h and 24 h post-electroporation. (D) Schematic of single and co-transfection approach using CD19-CAR ± CCR7 mRNA. Created with BioRender.com . (E) Representative plots of mock-transfected control, CD19-CAR-only, CCR7-only, and CD19-CAR + CCR7 co-transfected T cells, showing CD19-CAR and CCR7 expression 8 h post-transfection. (F) Viability of T cells following single and dual mRNA transfection, assessed by live/dead staining 8 h post-transfection. (G–I) Quantification of CD19-CAR-only versus CD19-CAR + CCR7 co-expression: CD19-CAR + frequency (G), CD19-CAR geometric mean fluorescence intensity (H), and CCR7 geometric mean fluorescence intensity (I) in CD3 + T cells, 8 h after mRNA transfection ( n = 8 donors). (J) Schematic of multiplexing approach using four IVT mRNAs (CD19-CAR, CCR7, CXCR3, and GFP). Created with BioRender.com . (K–N) Flow cytometric analysis of four-mRNA multiplexing showing frequency of CD19-CAR + GFP + double-positive cells (K and L) and geometric mean fluorescence intensity of CXCR3 (M) and CCR7 (N), 8 h post-transfection ( n = 3 donors). Statistical analysis between subpopulations was performed by one-way ANOVA with Tukey’s post hoc test or paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from the indicated number of independent donors.

    Article Snippet: PBMCs were isolated from healthy donors using Biocoll (Biochrom) gradient centrifugation, and CD3 + T cells were enriched using magnetic cell separation with CD3 Microbeads (Miltenyi Biotec).

    Techniques: Transfection, Expressing, Isolation, Electroporation, Cotransfection, Control, Staining, Fluorescence, Multiplexing

    Memory phenotype characterization of IVT mRNA-transfected CD19-CAR T cells (A) Representative flow cytometry plots showing the gating strategy for CD8 + memory T cell subsets in primary human CD3 + -enriched T cells. Subsets were defined by CD3 + , CD4 – , CD8 + , and CCR7/CD45RA expression as follows: naive like (T naive like ; CCR7 + CD45RA + ), central memory (T CM ; CCR7 + CD45RA – ), effector memory (T EM ; CCR7 – CD45RA – ), and terminally differentiated effector (T EMRA ; CCR7 – CD45RA + ). (B) Frequencies of CD4 + and CD8 + T cells within CD19-CAR + populations compared with mock-transfected controls after electroporation or LNP transfection. (C and D) Geometric mean fluorescence intensity (gMFI) of CD19-CAR expression in bulk CD4 + (C) and CD8 + (D) T cell populations following electroporation or LNP-mediated transfection; representative experiment. (E and F) CD19-CAR surface expression across memory T cell subsets within the CD8 + population following electroporation (E) or LNP-mediated (F) mRNA delivery over 108 h post-transfection. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test (B) or by two-way repeated-measures ANOVA with Šidák’s multiple-comparison test (E and F). ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from n = 4 independent donors, unless stated otherwise.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation

    doi: 10.1016/j.omtn.2026.102929

    Figure Lengend Snippet: Memory phenotype characterization of IVT mRNA-transfected CD19-CAR T cells (A) Representative flow cytometry plots showing the gating strategy for CD8 + memory T cell subsets in primary human CD3 + -enriched T cells. Subsets were defined by CD3 + , CD4 – , CD8 + , and CCR7/CD45RA expression as follows: naive like (T naive like ; CCR7 + CD45RA + ), central memory (T CM ; CCR7 + CD45RA – ), effector memory (T EM ; CCR7 – CD45RA – ), and terminally differentiated effector (T EMRA ; CCR7 – CD45RA + ). (B) Frequencies of CD4 + and CD8 + T cells within CD19-CAR + populations compared with mock-transfected controls after electroporation or LNP transfection. (C and D) Geometric mean fluorescence intensity (gMFI) of CD19-CAR expression in bulk CD4 + (C) and CD8 + (D) T cell populations following electroporation or LNP-mediated transfection; representative experiment. (E and F) CD19-CAR surface expression across memory T cell subsets within the CD8 + population following electroporation (E) or LNP-mediated (F) mRNA delivery over 108 h post-transfection. Statistical analysis was performed by one-way ANOVA with Tukey’s post hoc test (B) or by two-way repeated-measures ANOVA with Šidák’s multiple-comparison test (E and F). ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from n = 4 independent donors, unless stated otherwise.

    Article Snippet: PBMCs were isolated from healthy donors using Biocoll (Biochrom) gradient centrifugation, and CD3 + T cells were enriched using magnetic cell separation with CD3 Microbeads (Miltenyi Biotec).

    Techniques: Transfection, Flow Cytometry, Expressing, Electroporation, Fluorescence, Comparison

    Functional characterization of CD19-CAR mRNA transfected T cells following antigen encounter (A) Experimental workflow of the overnight stimulation assay: mock-transfected and mRNA-transfected CD19-CAR T cells were stimulated with NALM6 (CD19 + ) cells for 16 h in the presence of brefeldin A to capture intracellular cytokine production by flow cytometry. Created with BioRender.com . (B) Representative flow cytometry plots showing activation marker expression (CD137 and CD154) in CD3 + T cells with (stimulated) and without (unstimulated) target cell stimulation. Comparisons are shown for electroporated (left) and LNP-transfected (right) CD19-CAR T cells. (C) Frequencies of activated (CD137 + and/or CD154 + ) CD3 + , CD4 + , and CD8 + T cell populations, comparing electroporation and LNP delivery methods. Data are background-subtracted. (D) Intracellular effector cytokine production (IFN-γ and TNF-α) within activated CD3 + , CD4 + , and CD8 + T cell populations. Data showing the relative increase in cytokine-producing T cells for LNP transfection normalized to electroporation. Statistical analysis was performed by paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from n = 4 independent donors.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation

    doi: 10.1016/j.omtn.2026.102929

    Figure Lengend Snippet: Functional characterization of CD19-CAR mRNA transfected T cells following antigen encounter (A) Experimental workflow of the overnight stimulation assay: mock-transfected and mRNA-transfected CD19-CAR T cells were stimulated with NALM6 (CD19 + ) cells for 16 h in the presence of brefeldin A to capture intracellular cytokine production by flow cytometry. Created with BioRender.com . (B) Representative flow cytometry plots showing activation marker expression (CD137 and CD154) in CD3 + T cells with (stimulated) and without (unstimulated) target cell stimulation. Comparisons are shown for electroporated (left) and LNP-transfected (right) CD19-CAR T cells. (C) Frequencies of activated (CD137 + and/or CD154 + ) CD3 + , CD4 + , and CD8 + T cell populations, comparing electroporation and LNP delivery methods. Data are background-subtracted. (D) Intracellular effector cytokine production (IFN-γ and TNF-α) within activated CD3 + , CD4 + , and CD8 + T cell populations. Data showing the relative increase in cytokine-producing T cells for LNP transfection normalized to electroporation. Statistical analysis was performed by paired t test. ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SD from n = 4 independent donors.

    Article Snippet: PBMCs were isolated from healthy donors using Biocoll (Biochrom) gradient centrifugation, and CD3 + T cells were enriched using magnetic cell separation with CD3 Microbeads (Miltenyi Biotec).

    Techniques: Functional Assay, Transfection, Flow Cytometry, Activation Assay, Marker, Expressing, Cell Stimulation, Electroporation

    Functional characterization of CD19-CAR T cells produced by LNP-mediated versus electroporation-based mRNA delivery (A) Experimental workflow: electroporated and LNP-transfected T cells were assessed in an in vitro transwell assay, first migrating toward CCL21 for 3 h, followed by co-culture with NALM6 target cells (CD19 + GFP + ). Killing efficiency was monitored over 28 h with 4-h intervals using live-cell imaging. Created with BioRender.com . (B) Killing efficacy of NALM6 (CD19 + GFP + ) target cells using untouched, mock-transfected and CD19-CAR mRNA transfected T cells (EP and LNP) over 28 h assessed using live-cell imaging every 4 h. (C) Area under the curve (AUC) analysis of total killing capacity over the 28-h observation period for the same groups relative to untouched T cells. (D) Fold increase of migrated CD3 + T cells toward CCL21 chemokine normalized to untouched T cells comparing LNP and electroporation delivery methods for mock-transfected and CD19-CAR mRNA transfected T cells analyzed using flow cytometry. (E) Flow cytometric analysis of exhaustion marker expression (TIM-3 and LAG-3) in CD3 + , CD4 + and CD8 + T cell populations following cytotoxic activity of LNP-transfected T cells normalized to electroporated T cells. (F) Mean percentage of CAR T cells expressing zero, one, two, or three exhaustion markers in electroporated T cells (upper) and LNP-transfected CD19-CAR T cells (lower) following cytotoxic activity. (G) Supernatants from migrated T cell killing assays were collected and analyzed for pro-inflammatory cytokines. Mean levels of granzyme B, IFN-γ, TNF-α, IL-8, and IL-10 are shown. Normalized to CD19-CAR frequency for each sample. Statistical analysis for differences between subpopulations was performed by Friedman test followed by Dunn’s multiple comparison test (C, D, and G) or paired t test (E). ∗ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SEM from n = 4 independent donors.

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation

    doi: 10.1016/j.omtn.2026.102929

    Figure Lengend Snippet: Functional characterization of CD19-CAR T cells produced by LNP-mediated versus electroporation-based mRNA delivery (A) Experimental workflow: electroporated and LNP-transfected T cells were assessed in an in vitro transwell assay, first migrating toward CCL21 for 3 h, followed by co-culture with NALM6 target cells (CD19 + GFP + ). Killing efficiency was monitored over 28 h with 4-h intervals using live-cell imaging. Created with BioRender.com . (B) Killing efficacy of NALM6 (CD19 + GFP + ) target cells using untouched, mock-transfected and CD19-CAR mRNA transfected T cells (EP and LNP) over 28 h assessed using live-cell imaging every 4 h. (C) Area under the curve (AUC) analysis of total killing capacity over the 28-h observation period for the same groups relative to untouched T cells. (D) Fold increase of migrated CD3 + T cells toward CCL21 chemokine normalized to untouched T cells comparing LNP and electroporation delivery methods for mock-transfected and CD19-CAR mRNA transfected T cells analyzed using flow cytometry. (E) Flow cytometric analysis of exhaustion marker expression (TIM-3 and LAG-3) in CD3 + , CD4 + and CD8 + T cell populations following cytotoxic activity of LNP-transfected T cells normalized to electroporated T cells. (F) Mean percentage of CAR T cells expressing zero, one, two, or three exhaustion markers in electroporated T cells (upper) and LNP-transfected CD19-CAR T cells (lower) following cytotoxic activity. (G) Supernatants from migrated T cell killing assays were collected and analyzed for pro-inflammatory cytokines. Mean levels of granzyme B, IFN-γ, TNF-α, IL-8, and IL-10 are shown. Normalized to CD19-CAR frequency for each sample. Statistical analysis for differences between subpopulations was performed by Friedman test followed by Dunn’s multiple comparison test (C, D, and G) or paired t test (E). ∗ns, not significant; ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. Data represent mean ± SEM from n = 4 independent donors.

    Article Snippet: PBMCs were isolated from healthy donors using Biocoll (Biochrom) gradient centrifugation, and CD3 + T cells were enriched using magnetic cell separation with CD3 Microbeads (Miltenyi Biotec).

    Techniques: Functional Assay, Produced, Electroporation, Transfection, In Vitro, Transwell Assay, Co-Culture Assay, Live Cell Imaging, Flow Cytometry, Marker, Expressing, Activity Assay, Comparison